Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Open Access
- 9 April 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 395 (10234), 1407-1409
- https://doi.org/10.1016/s0140-6736(20)30858-8
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Lowering the Threshold of Lung Innate Immune Cell Activation Alters Susceptibility to Secondary Bacterial SuperinfectionThe Journal of Infectious Diseases, 2011
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- What does tumour necrosis factor excess do to the immune system long term?Annals Of The Rheumatic Diseases, 2005
- Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathologyEuropean Journal of Immunology, 2001
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000
- Role of Tyrosine Kinase Enzymes in TNF‐α and IL‐1 Induced Expression of ICAM‐1 and VCAM‐1 on Human Umbilical Vein Endothelial CellsScandinavian Journal of Immunology, 1997
- INTERSEPTCritical Care Medicine, 1996
- Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia.The Journal of Experimental Medicine, 1989
- INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITISThe Lancet, 1989